Markus Hinder

Markus Hinder

Auto-generated profile, based on publicly available information

Markus Hinder

Novartis, Forum 1 Basel Switzerland

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2021 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
DRDaniel J Rader
Daniel J Rader
EMEleftheria Maratos-Flier
Eleftheria Maratos-Flier
ANAmanda Nguyen
Amanda Nguyen
DHDoug Hom
Doug Hom
MFMichael Ferriere
Michael Ferriere
JWJessica Wilson
Jessica Wilson
Purpose To evaluate the safety and potential efficacy of LLF580, a genetically engineered variant of human fibroblast growth factor-21, for triglyceride lowering, weight loss, and hepatic fat reduction. Methods A multicenter, double-blind, parallel design trial in obese, mildly hypertriglyceridemic adults randomized (1:1) to LLF580 300 mg or placebo subcutaneously every 4 weeks for 3 doses. Results Of 64 randomized study participants, 61 (mean ± SD: age 45 ± 11 years, 49% male, 80/15/5% Caucasian/African American/other, body mass index 36.1 ± 3.8 kg/m2) received LLF580 (n = 30) or placebo (n = 31) at 7 research sites in the United States. LLF580 lowered serum triglycerides by 54% (least square mean placebo adjusted change from baseline), total cholesterol 7%, low-density lipoprotein cholesterol 12%, and increased high-density lipoprotein cholesterol 36% compared with placebo (all P < 0.001) over 12 weeks. Substantial reduction of liver fat of 52% over placebo (P < 0.001) was also demonstrated in the setting of improved liver function tests including alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase, the composite enhanced liver fibrosis score, and N-terminal type III collagen propeptide (all P < 0.05). Insulin and C-peptide levels and insulin resistance by homeostatic model assessment for insulin resistance were all lower, and adiponectin higher with LLF580 treatment compared with placebo, whereas fasting glucose and glycated hemoglobin were unchanged. Reductions in biomarkers of bone formation without differences in markers of bone resorption were observed. LLF580 was generally safe and well tolerated, except for higher incidence of generally mild to moderate gastrointestinal adverse effects. Conclusions In obese, mildly hypertriglyceridemic adults, LLF580 was generally safe and demonstrated beneficial effects on serum lipids, liver fat, and biomarkers of liver injury, suggesting it may be effective for treatment of select metabolic disorders including hypertriglyceridemia and nonalcoholic fatty liver disease. Assessments of longer term safety and efficacy are warranted. ClinicalTrials.gov Identifier NCT03466203

15 July 2021 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
STSusanne Tan
Susanne Tan
SIStanislav Ignatenko
Stanislav Ignatenko
FWFrank Wagner
Frank Wagner
ADAnuja Dokras
Anuja Dokras
JSJochen Seufert
Jochen Seufert
MHMarkus Hinder
Markus Hinder
Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism and insulin resistance. The dual sodium‐glucose co‐transporter 1/2 inhibitor (SGLT1/2i) licogliflozin (LIK066) ameliorates hyperinsulinism in patients with diabetes and obesity. This study examines the effect of licogliflozin on androgens in women with PCOS. In a multicentre, randomized, placebo‐controlled, double‐blind, 2‐week trial, patients with PCOS received licogliflozin 50 mg or placebo three times a day (TID). Changes in free testosterone (FT), other androgens and variables of insulin resistance were analysed. Concentration of FT did not change (TR LIK066 :TR PCB [FT]: 0.88; 90% CI: 0.70‐1.11; P = .353). Licogliflozin reduced androstendione (A4) by 19% (TR LIK066 :TR PCB [A4]: 0.81; 90% CI: 0.68‐0.99; P = .089) and dehydroepiandrosteron sulphate (DHEAS) by 24% (TR LIK066 :TR PCB [DHEAS]: 0.76; 90% CI: 0.65‐0.89; P = .008). Hyperinsulinaemia was reduced by 70% by licogliflozin (highest insulin concentration [MAXI]; TR LIK066 :TR PCB [MAXI]: 0·26; 90% CI:0.20‐0.34; P < .001 and area under the curve insulin [AUCI]; TR LIK066 :TR PCB [AUCI]: 0.32; 90% CI: 0.25‐0.41; P < .001). Diarrhoea and nausea occurred as common adverse events. Dual inhibition of SGLT1/2 ameliorates hyperinsulinaemia and hyperandrogenaemia in women with PCOS. Licogliflozin may represent a promising novel treatment option for PCOS.

1 August 2021 in Drug Discovery Today
Verified
Journal Article
Closed access
ASAlexander Schuhmacher
Alexander Schuhmacher
LWLucas Wilisch
Lucas Wilisch
MKMichael Kuss
Michael Kuss
Andreas KandelbauerAndreas Kandelbauer
Andreas Kandelbauer
MHMarkus Hinder
Markus Hinder
OGOliver Gassmann
Oliver Gassmann

1 October 2021 in Drug Discovery Today
Verified
Journal Article
Closed access
ASAlexander Schuhmacher
Alexander Schuhmacher
AGAlexander Gatto
Alexander Gatto
MKMichael Kuss
Michael Kuss
OGOliver Gassmann
Oliver Gassmann
MHMarkus Hinder
Markus Hinder

9 March 2016 in European Journal of Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
YHYi Han
Yi Han
SASurya Ayalasomayajula
Surya Ayalasomayajula
WPWei Pan
Wei Pan
FYFan Yang
Fan Yang
YYYaozong Yuan
Yaozong Yuan
GSGangadhar Sunkara
Gangadhar Sunkara

1 December 2021 in Drug Discovery Today
Verified
Journal Article
Closed access
ASAlexander Schuhmacher
Alexander Schuhmacher
CBClara Brieke
Clara Brieke
OGOliver Gassmann
Oliver Gassmann
MHMarkus Hinder
Markus Hinder
DHDominik Hartl
Dominik Hartl